November 12, 2018 08:31 AM EST

Novartis builds blockbuster case for Entresto, beating out a cheap ACE inhibitor — or not

John Carroll

Editor & Founder

Novartis execs got the positive data they were looking for from their PIONEER-HF study of Entresto to back accelerating sales of the heart medication. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis builds blockbuster case for Entresto, beating out a cheap ACE inhibitor — or not

John Carroll

Editor & Founder

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

No­var­tis builds block­buster case for En­tresto, beat­ing out a cheap ACE in­hibitor — or not

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Novartis builds blockbuster case for Entresto, beating out a cheap ACE inhibitor — or not